Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?

Yzet, Clara; Tse, Stacy S; Kayal, Maia; Hirten, Robert; Colombel, Jean-Frédéric

Yzet, Clara; Tse, Stacy S; Kayal, Maia; Hirten, Robert; Colombel, Jean-Frédéric.

Afiliación

Yzet C; Gastroenterology, Amiens University Hospital, Amiens, France.
Tse SS; Division of Gastroenterology, Mount Sinai Hospital, New York, NY, United States.
Kayal M; Division of Gastroenterology, Icahn School of Medicine, Mount Sinai, New York, NY, United States.
Hirten R; Division of Gastroenterology, Icahn School of Medicine, Mount Sinai, New York, NY, United States.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine, Mount Sinai, New York, NY, United States.

Curr Pharm Des ; 25(1): 57-63, 2019.

Article en En | MEDLINE | ID: mdl-30848194

Asunto(s)

Evaluación de Medicamentos; Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos; Enfermedades Inflamatorias del Intestino/terapia; Terapia Biológica; Humanos

Palabras clave

Drug development; adverse effect; biologics; clinical trials; inflammatory bowel disease; safety; side effect.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Evaluación de Medicamentos / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos Idioma: En Revista: Curr Pharm Des Año: 2019 Tipo del documento: Article País de afiliación: Francia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google